|Day Low/High||44.67 / 47.48|
|52 Wk Low/High||39.07 / 65.51|
Year-to-date revenues increased 15%, driven by increased SPINRAZA revenue
IONIS-HTT Rx is the first and only drug to demonstrate reduction of mutant huntingtin protein, the underlying cause of Huntington's disease, in patients
- PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea -
Investors in Ionis Pharmaceuticals Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IONS options chain for the new September 21st contracts and identified one put and one call contract of particular interest.
Webcast scheduled for Tuesday, August 7th at 11:30 a.m. Eastern Time
-TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life-
CARLSBAD, Calif., June 18, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
CARLSBAD, Calif., June 5, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Leggett & Platt, Inc. , according to The Online Investor.
Jim Cramer makes the calls on Alibaba, First American, Coherent, Ionis Pharmacuetical, Skechers USA, Corning, Bank of Internet and more.
Love the banks, then hate the banks. Love the industrials? Nope, they're out, too. Jim Cramer says it's ugly, but he would use the weakness in the upside surprises.
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological...
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOG, FGEN, GASS, GHC, SATS Downgrades: ALB, CFBK, CLI, DISCB, FORM, HCCI, IONS, KOP, LTC, MNRO, PNTR, SRE Initiations: FRAC, JELD, REVG Read on to get TheStreet Quant Ratings' detailed report:
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc.
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of...
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the end of study results from ENDEAR, the Phase 3 study of SPINRAZA ® (nusinersen) for the treatment of spinal muscular atrophy...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ionis Pharmaceuticals Inc , where a total of 10,049 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 75.1% of IONS's average daily trading volume over the past month of 1.3 million shares.
Biogen (NASDAQ: BIIB) presented new data demonstrating that earlier initiation of treatment with SPINRAZA ® (nusinersen) may improve motor function outcomes in infants and children with spinal muscular atrophy...
Jim Cramer says the market may be shaking off bad news and threats, but recent positivity is unusual. Don't speculate, be diversified and don't feel bad about taking profits.
Jim Cramer is bullish on Alibaba, Qorvo, Abbott Laboratories, Square, and Baozun.
The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 1,283,370 share increase in total short interest for Ionis Pharmaceuticals Inc , to 12,036,594, an increase of 11.93% since 07/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Evercore ISI analyst Josh Schimmer is bullish on biotech.
Ionis retained all rights to inotersen and IONIS-FB-LRx as part of reprioritizing its pipeline and a strategic review of its Rare Diseases business.
The most recent short interest data has been released for the 07/31/2017 settlement date, which shows a 2,021,584 share decrease in total short interest for Ionis Pharmaceuticals Inc , to 10,753,224, a decrease of 15.82% since 07/14/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.